Report : North America Lipidomics Equipment Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Targeted and Untargeted), Offerings {MS-Based Lipidomics Techniques [Mass Spectrometers Equipped with Ion Sources (Turbo-) ESI/Nano-ESI/APCI, Autosamplers, Micropumps, UV Detectors, UPLC, Variable-Length Fluorescence Detectors, and Others], Assays For Lipid Metabolism, Lipid Flux Using Heavy Isotope-Labeled Precursors, Software & Services, and Others}, Services (Biomarker Identification, Bioinformatic Analysis & Data Interpretation, Molecular Analysis of a Broad Spectrum of Phospholipids (Lipid Fingerprinting), Analysis & Identification of Unusual Lipids, Semiquantitative & Quantitative Analysis, Lipid Flux Studies, and Others), and End User (Molecular Research, Cellular Research, Clinical Research, Tissue & Organ Research, Data Research, Organism Research, Technical Services & Prototyping, Production, and Others) 

At 14.6% CAGR, the North America Lipidomics Equipment Market is projected to be worth US$ 943.65 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the North America lipidomics equipment market was valued at US$ 415.85 million in 2022 and is expected to reach US$ 943.65 million by 2028, registering a CAGR of 14.6% from 2022 to 2028. Growing applications of lipidomics in biomedical sciences and technological advancements in mass spectrometry are the critical factors attributed to the North America lipidomics equipment market expansion.        

Lipidomics, an emerging discipline of biomedical sciences, involves the characterization of complex lipidomes. It is a quantitative and complete depiction of a set of lipid species present in an organism. The lipidome characterization is based on a system-level quantitation and the detection of several networks & pathways of cellular lipids, along with their interaction with other moieties and proteins. Determining lipid profiles and comparing the profiles obtained for two physiologically linked conditions can help understand lipid metabolism pathways, which further can be employed for the development of diagnostic methods for cancer, cardiovascular disorders, eye diseases, and other diseases. Lipidomics plays a pivotal role in pharmacological research, especially in new drug discovery and development processes. It is also applied for toxicity evaluation, molecule screening, preclinical testing, etc. For example, de novo lipogenesis inhibitors are of major interest among researchers due to their pro-apoptotic effects on cancerous tissues. Lipidomics can also be used to screen such anticancer drug candidates for their ability to inhibit de novo lipid synthesis and for identifying novel drug efficacy biomarkers. Thus, a wide range of applications of lipidomics in biomedical sciences boosts the demand for lipidomics equipment, thereby propelling the North America lipidomics equipment market growth.  

On the contrary, premium product pricing hurdles the growth of North America lipidomics equipment market.   

Based on type, the North America lipidomics equipment market is bifurcated into targeted and untargeted. The targeted segment held 62.3% share of North America lipidomics equipment market in 2022, amassing US$ 259.17 million. It is projected to garner US$ 583.97 million by 2028 to expand at 14.5% CAGR during 2022–2028.     

Based on offerings, the North America lipidomics equipment market is segmented into MS-based lipidomics techniques, assays for lipid metabolism, lipid flux using heavy isotope-labeled precursors, software & services, and others. The MS-based lipidomics techniques segment held 66.4% share of North America lipidomics equipment market in 2022, amassing US$ 276.13 million. It is projected to garner US$ 624.07 million by 2028 to expand at 14.6% CAGR during 2022–2028. The MS-based lipidomics techniques segment is further categorized into mass spectrometers equipped with ion sources (turbo-) ESI/nano-ESI/APCI, autosamplers, micropumps, UV detectors, UPLC, variable-length fluorescence detectors, and others. 

Based on services, the North America lipidomics equipment market has been segmented into biomarker identification, bioinformatic analysis & data interpretation, molecular analysis of a broad spectrum of phospholipids (lipid fingerprinting), analysis & identification of unusual lipids, semiquantitative & quantitative analysis, lipid flux studies, and others. The biomarker identification segment held 29.7% share of North America lipidomics equipment market in 2022, amassing US$ 123.49 million. It is projected to garner US$ 279.09 million by 2028 to expand at 14.6% CAGR during 2022–2028.     

Based on end user, the North America lipidomics equipment market is segmented into molecular research, cellular research, clinical research, tissue & organ research, data research, organism research, technical services & prototyping, production, and others. The molecular research segment held 27.3% share of North America lipidomics equipment market in 2022, amassing US$ 113.39 million. It is projected to garner US$ 259.33 million by 2028 to expand at 14.8% CAGR during 2022–2028.          

Based on country, the North America lipidomics equipment market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 83.5% share of North America lipidomics equipment market in 2022. It was assessed at US$ 347.20 million in 2022 and is likely to hit US$ 787.48 million by 2028, exhibiting a CAGR of 14.6% during the forecast period.       

Key players dominating the North America lipidomics equipment market are Agilent Technologies, Inc.; Bruker; Cayman Chemical; Creative Proteomics; IonBench; Metabolon, Inc.; PerkinElmer Inc.; Sciex; Shimadzu Corporation.; and Thermo Fisher Scientific Inc., among others.  

  • In June 2022, PerkinElmer Inc. launched the GC 2400 platform, an advanced, automated gas chromatography (GC), headspace sampler and GC/mass spectrometry (GC/MS) solution designed to help lab teams simplify lab operations, drive precise results, and perform more flexible monitoring. The platform’s icon-driven, 21 CFR Part 11 compliant PerkinElmer SimplicityChrom Chromatography Data System (CDS) software reduces user training and guides teams through their entire GC workflow. The software interface is also customizable to address user’s unique data, notification, and diagnostic needs.  

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com

Download Free PDF Brochure